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Purpose: To assess the ability of preoperative variables to predict extracapsular ex-
tension (ECE) and positive surgical margin (PSM) in radical prostatectomy patients 
with prostate-specific antigen (PSA) levels of less than 10 ng/ml.
Materials and Methods: From January 2008 to December 2009, 121 patients with pros-
tate cancer with PSA levels lower than 10 ng/ml who underwent radical prostatectomy 
were enrolled in the study. The differences in clinical factors (age, PSA, PSA density 
[PSAD], digital rectal examination [DRE] positivity, positive magnetic resonance 
imaging [MRI], Gleason sum, positive core number, and positive biopsy core percent-
age) with ECE and the presence of positive margins were determined and their in-
dependent predictive significances were analyzed.
Results: The ECE-positive patients had higher PSA, PSAD, and MRI-positive percen-
tages, and PSM patients had higher PSA, PSAD, MRI-positive percentages, Gleason 
sum, and positive biopsy core percentages for prostate cancer. In the multivariate anal-
ysis, PSAD and MRI positivity were the best independent predictors for ECE, and PSA 
and PSAD were the best independent predictors of PSM. By receiver operating charac-
teristic curve analysis, PSAD had better discriminative area under the curve value than 
did PSA for ECE (0.765 vs 0.661) and PSM (0.780 vs 0.624). The best predictive PSAD 
value was 0.29 ng/ml/cc for ECE and 0.27 ng/ml/cc for PSM.
Conclusions: PSAD has relevance to ECE (plus MRI findings) and PSM (plus PSA). 
PSAD might be a powerful predictor of ECE and PSM preoperatively in patients under-
going a radical prostatectomy with PSA levels of less than 10 ng/ml. 
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INTRODUCTION 
Prostate cancer is best cured by radical prostatectomy 
when the disease is organ-confined and the pathologic 
stage after surgery is known to be related with cancer 
control. Predicting the pathological stage of a prostate can-
cer is important for deciding on a treatment strategy, but 
current clinical methods, including imaging or examina-
tion tools, are still of limited value for given patients, espe-
cially those with intermediate risk [1,2].
Prostate-specific antigen (PSA) has been used as a crite-
rion for consideration for prostate biopsy, and 30% to 35% 
of men with PSA less than 10 ng/ml will be found to have 
prostate cancer [3]. Usually, 80% of men with PSA less than 
4.0 ng/ml have pathologically proven organ-confined dis-
ease, and 66% of men with PSA levels between 4.0 and 10.0 Korean J Urol 2011;52:809-814
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TABLE 1. Perioperative characteristics of 121 radical prosta-
tectomy patients with PSA＜10 ng/ml
Variable Value
Mean age (yr)
Mean PSA (ng/ml) 
Mean gram:prostate volume (range)
Median ng/ml/cc:PSAD (range)
DRE positivity for ECE number (%) 
MRI positivity for ECE number (%)
Mean biopsy core number (range)
Mean biopsy Gleason score (range)
Mean number of positive core (range)
Mean percentage of positive biopsy 
core (range)
Extracapsular extension number (%)
Positive surgical margin number (%)
    pT2
    pT3
62.60 (46-75)
        6.65 (3.35-9.79)
27.89 (12-75)
        0.31 (0.07-1.10)
     26 (21.49)
     18 (14.88)
  8.7 (5-13)
6.68 (6-9)
2.48 (1-6)
        26.03 (7.69-62.50)
     35 (28.92)
     30 (24.79)
     8 (6.61)
PSA: prostate-specific antigen, PSAD: prostate-specific antigen 
density, DRE: digital rectal examination, ECE: extracapsular ex-
tension,  MRI: magnetic resonance imaging
ng/ml have organ-confined disease [4]. In other words, 20% 
to 34% of prostate cancer patients have extraprostatic dis-
ease regardless of low to intermediate PSA levels (less than 
10 ng/ml). Shinohara et al reported the ability of the serum 
PSA level to predict the pathologic stage [5]. On the other 
hand, Partin et al failed to utilize serum PSA to determine 
the pathologic stage of clinically localized prostate cancer. 
They could not find a correlation between serum PSA and 
pathologic stage [6]. 
Because of variable PSA production by individual pros-
tate cancer cells and wide variation in the contribution of 
benign prostatic hyperplasia to serum PSA levels, risk 
analysis based on only the PSA level seems incomplete if 
the PSA level is low to intermediate. 
Extracapsular extension (ECE) and positive surgical 
margin (PSM) are important findings because of their im-
plications for tumor biology, disease recurrence, and can-
cer survival [7,8]. In this study, we tried to determine the 
correlation between preoperative predictive factors such 
as digital rectal examination (DRE) findings, magnetic res-
onance imaging (MRI) findings, PSA with prostate-specific 
antigen density (PSAD), and biopsy characteristics and 
ECE and PSM as pathological outcomes in 121 radical pros-
tatectomy patients with PSA less than 10 ng/ml. 
MATERIALS AND METHODS 
From January 2008 to December 2009, we evaluated 121 
prostate cancer patients with PSA lower than 10 ng/ml who 
underwent radical prostatectomy performed by the stand-
ard transperitoneal approach with the interfacial techni-
que as previously reported [9]. Patients who had under-
gone previous surgery for benign prostatic hypertrophy or 
who had received hormonal or radiation therapy previous 
to robot-assisted laparoscopic radical prostatectomy 
(RALP) were excluded. These 121 men underwent trans-
rectal prostate biopsies owing to elevated PSA levels of ≥4 
ng/ml or abnormal DRE findings or abnormal hypoechoic 
lesions on transrectal ultrasonography (TRUS). For PSA 
testing, patients’ serum was obtained before prostatic 
manipulations. Prostate volume was defined by measuring 
the height (H), width (W), and length (L) of the prostate 
from two selected orthogonal views and calculating the vol-
ume (V) as that of the corresponding ellipsoid formula: 
V=0.52xWxHxL [10]. PSAD was obtained by dividing se-
rum PSA levels by the individual prostate volumes meas-
ured by TRUS. All patients underwent a DRE and endor-
ectal MRI to determine preoperative prostate status. 
Tumors that MRI showed to be attached to the prostate cap-
sule or tumors with a localized bulge were classified as sus-
pected extracapsular extension. Systematic biopsies were 
obtained for 6 to 13 cores from separate regions, with at 
least 3 cores from each of both lobes. The total core number 
and positive core number of biopsies per patient were 
verified. Biopsy specimens were taken from different areas 
of the prostate assigned to proper Gleason scores. 
Pathological staging of the radical prostatectomy speci-
men was performed and organ-confined cancer was des-
ignated as long as the capsule was not penetrated. 
Histopathologic data of radical prostatectomy specimens 
including capsule penetration and surgical margin were 
recorded. ECE was defined as a tumor extending outside 
of the prostate into the periprostatic soft tissues; accord-
ingly, tumor invasion of the prostatic capsule without pen-
etration was not ECE. 
Once the patients were identified, we performed uni-
variate analysis to determine the differences by pathologic 
outcome (ECE positivity and PSM) in age, PSA, PSAD, 
DRE positivity, and MRI positivity. Biopsy characteristics 
(Gleason sum, number of positive cores, and positive biopsy 
core percentage for prostate cancer) were also compared. 
Next, the significant predictors were entered into a logistic 
regression test to determine their independent predictive 
significance. All statistical analysis was performed by us-
ing the Mann Whitney U-test, Pearson's chi-square test for 
univariate analysis, and logistic regression for multi-
variate analysis. Receiver operating characteristic (ROC) 
curves were used to compare the diagnostic power and de-
termine the cutoff value associated with ECE and PSM 
positivity. SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) 
was used and a p-value below 0.05 was considered statisti-
cally significant.
RESULTS
Table 1 lists the patients’ characteristics. The patients’ 
mean age was 62.6 years (range, 46 to 75 years). The mean 
pre-biopsy PSA level was 6.65 mg/l, mean prostate volume 
was 27.89 g, and mean PSAD was 0.31 (range, 0.07 to 1.10). 
Twenty-six patients had palpable tumors and 18 patients 
had ECE on MRI. The median number of total cores was Korean J Urol 2011;52:809-814
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TABLE 2. Uni-variate and multi-variate analysis of clinical and biopsy features for predicting ECE of 121 radical prostatectomy 
patients
Extracapsular extension
Uni-variate
analysis
Multi-variate
analysis
Negative 
(n=93)
Positive (n=28) p-value p-value Odds ratio
95% confidence 
interval
Age (yr)
PSA (ng/ml)
Prostate volume (g)
PSAD (ng/ml/cc)
DRE positivity for ECE (%)
MRI positivity for ECE (%)
Mean biopsy Gleason score
Mean number of positive core
Mean percentage of positive biopsy core
62.66
  6.32 
30.28
  0.26
20 (21.51)
7 (7.53)
  6.51
  2.28
24.34
62.50
  7.37
25.97
  0.43
  6 (21.43)
11 (39.28)
  6.86
  2.86
28.38
0.90
0.03
0.08
0.00
0.15
0.01
0.21
0.17
0.06
0.06
0.00
0.02
  1.78
16.23
    3.583
0.558-0.763
0.663-0.849
PSA: prostate-specific antigen, PSAD: prostate-specific antigen density, DRE: digital rectal examination, ECE: extracapsular ex-
tension, MRI: magnetic resonance imaging
FIG. 1. (A) Receiver operating characteristic (ROC) curves comparing prostate-specific (PSAD, dotted line) and PSA (line) for 
extracapsular extension. (B) ROC curves comparing PSAD (dotted line) and prostate-specific antigen (PSA, line) for positive surgical 
margin.
8.7. The percentage of positive cores was derived from the 
number of positive biopsy cores divided by the total number 
of biopsy cores per patient multiplied by 100. The median 
positive core number and the percentage of positive cores 
were 2.48 (range, 1 to 6) and 26.03% (range, 7.69% to 
62.50%), respectively. 
Table 2 shows the association of clinical and biopsy fea-
tures with ECE in radical prostatectomy patients. By uni-
variate analysis, ECE-positive patients had higher PSA 
(7.37 vs. 6.32 ng/ml), PSAD (0.43 vs. 0.26 ng/ml/cc) level, 
and MRI positivity (39.28% vs. 7.53%). In the multivariate 
analysis, PSAD and MRI positivity were the best in-
dependent predictors of ECE. In the ROC curve analysis 
of PSA and PSAD, PSAD showed better discriminative 
AUC value (0.765) than did PSA (0.661) for ECE (Fig. 1A). 
In Table 3, the analysis of associated factors for PSM 
showed that PSM patients had higher PSA (7.42 vs. 6.28 
ng/ml), PSAD (0.44 vs. 0.25 ng/ml/cc) level, and MRI pos-
itivity for ECE (26.01% vs. 12.24%). As for biopsy charac-
teristics, Gleason sum (6.97 vs. 6.25) and percentage of bi-
opsy cores positive for prostate cancer (29.92% vs. 24.14%) 
were higher in PSM patients. In the multivariate analysis, 
however, only PSA and PSAD were independent predictors 
of PSM statistically. The ROC curve showed diagnostic val-
ue of PSA and PSAD for PSM, and PSAD had better dis-
criminative AUC value (0.780) than did PSA (0.624) (Fig. 
1B). The best predictive PSAD value for ECE was 0.29 
ng/ml/cc (sensitivity 0.72, specificity 0.68) and 0.27 
ng/ml/cc (sensitivity 0.82, specificity 0.67) for PSM.
DISCUSSION
Pathological stage is usually predicted preoperatively to 
evaluate the possibility of cure by a particular therapy. Korean J Urol 2011;52:809-814
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TABLE 3. Uni-variate and multi-variate analysis of clinical and biopsy features for predicting positive surgical margin (PSM) of 121 
radical prostatectomy patients
Surgical margin
Uni-variate
analysis
Multi-variate
analysis
Negative 
(n=98)
Positive (n=23) p-value p-value Odds ratio
95% confidence
interval
Age (yr)
PSA (ng/ml)
Prostate volume (g)
PSAD (ng/ml/cc)
DRE positivity for ECE (%)
MRI positivity for ECE (%)
Mean biopsy Gleason score
Mean number of positive core
Mean percentage of positive biopsy core
62.67
  6.28
29.69
  0.25
21 (21.43)
12 (12.24)
  6.25
  2.34
24.14
62.47
  7.42
26.97
  0.44
  5 (21.74)
6 (26.0)
  6.97
  2.73
29.91
0.87
0.02
0.11
0.00
0.39
0.02
0.14
0.37
0.03
0.04
0.00
0.07
0.10
  2.38
20.29
  1.83
  1.81
0.515-0.734
0.689-0.871
PSA: prostate-specific antigen, PSAD: prostate-specific antigen density, ECE: extracapsular extension, DRE: digital rectal examina-
tion, MRI: magnetic resonance imaging
Reliable assessment of organ-confined prostatic cancer 
would be the best available method for complete removal 
without increasing the incidence of avoidable PSMs. 
Several established reports have tried to show the proba-
bility of PSM or ECE positivity by use of preoperative varia-
bles, such as clinical stage, PSA, and biopsy features 
[7,10-12].   
Despite preoperative staging with the use of these pa-
rameters, pathologic evaluation shows that a significant 
number of patients undergoing radical prostatectomy have 
extraprostatic disease and positive resection margins. 
Patients with organ-confined prostatic cancer have sig-
nificantly greater 5 year disease-free survival than do 
those with disease that is not organ-confined, and several 
studies have shown that PSM is an independent adverse 
predictor of pathologic outcome and significantly corre-
lates with the progression-free survival rate [11,13-15].
Former studies have shown that combining Gleason 
score, clinical stage, and PSA allows the estimation of or-
gan-confined prostate cancer. However, for the inter-
mediate-risk patient group, little additional information 
may be expected from those characteristics for predicting 
organ-confined disease [16,17]. In our study of 121 prostate 
cancer patients with a low to intermediate PSA level, biop-
sy Gleason score, DRE positivity, and mean number of pos-
itive cores showed no significant relationship. It is well 
known that biopsy features, such as tumor length, the pro-
portion of cancer involvement, number of positive cores, 
and the proportion of positive cores are predictive parame-
ters of ECE and cancer-related outcomes [18-20]. The his-
topathological features of prostate cancer grade and extent 
in needle biopsies have been used to predict cancer grade, 
tumor volume, and pathological stage in the prostate. The 
Gleason grade on needle biopsies has been demonstrated 
to be predictive of stage, and the number of positive cores 
in the biopsy was the most useful predictor of tumor size 
[21-23]. Equally, maximum tumor length was the best in-
dependent predictor of ECE and the number of positive bi-
opsies was the most useful single parameter with a positive 
predictive value of 83% in 274 lobes and a negative pre-
dictive value of 55% [7,13]. 
Pretreatment PSA, highest biopsy Gleason sum, and 
percentage of positive biopsy cores for cancer were the three 
most significant independent predictors of pathologic 
stage after radical prostatectomy in a recent study [24]. But 
cancer volume in the prostatectomy specimens was weakly 
or not correlated with the number of positive biopsies, total 
length of cancer in biopsies, and the percent of Gleason 
grade 4/5 on biopsies. Therefore, with these critical param-
eters from the biopsy specimens, Noguchi et al were unable 
to estimate cancer volume in the radical prostatectomy 
specimen on an individual basis [25]. In our data, PSM pa-
tients had a higher percentage of positive biopsy cores with 
no statistical significance. 
Generally, PSA is a strong predictor of tumor aggre-
ssiveness. Noldus and Stamey reported a strong correla-
tion (r=0.70) between preoperative PSA and the pathologi-
cally measured cancer volume. This correlation was not 
shown when they investigated larger numbers of patients 
[26]. PSA alone cannot predict the cancer volume reliably. 
PSA elevation produced by benign prostatic hyperplasia 
and advancing age decreases the reliability of serum PSA 
as a predictive parameter for cancer volume [5,6]. In an at-
tempt to improve the ability to predict organ-confined dis-
ease, Seaman et al tested the efficacy of PSAD. These inves-
tigators found greater accuracy predicting organ-confined 
disease with PSAD. Patients who have low PSAD values 
are ideal candidates for radical prostatectomy, and PSAD 
was a better predictor of final pathologic stage than 
Gleason score [27]. Taneja et al reported that the AUC for 
predicting the ECE of prostate tumors was 0.62 and 0.69 
for complexed serum PSA and complexed PSAD, re-
spectively [28]. These findings were supported by those of 
Naya et al who reported an AUC of 0.54 and 0.70 for com-Korean J Urol 2011;52:809-814
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plexed PSA and complexed PSAD, respectively [29]. Our 
study showed a better discriminative AUC value of PSAD 
for ECE (0.765) and for PSM (0.780) than previous reports. 
These results could be significant because of the narrow 
spectrum of enrolled patients with PSA less than 10 ng/ml. 
In general, PSAD is a better predictor of prostate cancer 
in men with PSA levels of 4-10 ng/ml, especially when ultra-
sound-determined measurements of prostate volume are 
available. This suggests that PSAD is a powerful parame-
ter for estimating tumor volume in the gray zone of prostate 
cancer regardless of patient race or age. Our data showed 
more accuracy of PSAD in predicting stage, which could be 
related to the small volume of the Asian race; more interna-
tional study will be needed [27]. As we know, this is the first 
study about the relationship between PSM and PSAD. 
Furthermore, like our result for ECE, Ishida et al reported 
that the pathological stage was found to be significantly 
correlated with the MRI findings but not the DRE findings 
[11]. 
Accurate cancer staging is critical for selecting the most 
appropriate treatment option in prostate cancer. 
Currently available predictive efforts for stage are compli-
cated, so we tried to simplify the related factors. In our 
study, we were able to show a significant predictive power 
and cutoff value of PSAD in terms of ECE and PSM com-
pared with PSA. This study had some limitations, includ-
ing its retrospective manner and lack of data about actual 
pathologically measured cancer volume. Although no sin-
gle parameter should be used in clinical practice to increase 
the ability to predict the presence of unfavorable pathologic 
outcomes, PSAD can be a useful and very effective predictor 
of ECE and PSM as a tool to reflect the tumor burden, and 
we can counsel patients with discretion regarding the like-
lihood of complete cancer control.
CONCLUSION
PSAD has relevance to ECE (plus MRI findings) and PSM 
(plus PSA). Although various clinical factors could sig-
nificantly increase adequate cancer control, PSAD could be 
a useful and powerful predictor for ECE and PSM as a pre-
operative characteristic in radical prostatectomy patients 
with PSA less than 10 ng/ml. However, our study was con-
ducted in two centers with 94 RALP cases and 27 RRP cases 
under three surgeons. Thus, larger and single-center stud-
ies will be needed.
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